

## Methotrexate

## Chemical Properties

CAS No. : 59-05-2


Formula: C<sub>20</sub>H<sub>22</sub>N<sub>8</sub>O<sub>5</sub>

Molecular Weight: 454.44

Keep away from direct sunlight

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Methotrexate (WR19039) is a folate analog, an inhibitor of the dihydrofolate reductase DHFR. Methotrexate has antimetabolic, antitumor, and immunosuppressive activities, and is commonly used in rheumatoid arthritis and various tumors.
Targets(IC50)	Apoptosis, Antifolate, ADC Cytotoxin, Dehydrogenase, DNA/RNA Synthesis
In vitro	<p><b>METHODS:</b> Six pediatric leukemia and lymphoma cell lines, NALM-6, NALM-16, JURKAT, CEM, RAMOS, and NAMALWA, were treated with Methotrexate (0.002-5 μM) for 120 h, and the proliferation inhibitory activity of the cells was assayed using the SRB method.</p> <p><b>RESULTS:</b> The median IC<sub>50</sub> of Methotrexate against tumor cells was 78 nM, and the IC<sub>50</sub> of the six tumor cells ranged from 33-133 nM. [1]</p> <p><b>METHODS:</b> Human ovarian cancer cells SKOV-3 were treated with Methotrexate (15-50 μM) for 24 h. Apoptosis was detected using AO/EtBr probe.</p> <p><b>RESULTS:</b> Methotrexate induced apoptosis in SKOV-3 cells. [2]</p>
In vivo	<p><b>METHODS:</b> To test for chronic toxicity, Methotrexate (0.25-6 mg/kg) was administered intraperitoneally to C57BL/6, DBA/2, and C3H mice five times per week for 12-18 months.</p> <p><b>RESULTS:</b> The 0.25-2 mg/kg dose was well tolerated with minimal cytostasis in lymphoid tissues, testis and skin. 3-6 mg/kg dose produced well-known acute to subacute hematopoietic and gastrointestinal injuries leading to early death. [3]</p> <p><b>METHODS:</b> To examine the mode of action in different types of rheumatoid arthritis (RA) and multiple sclerosis (MS) models, Methotrexate (0.1-5 mg/kg) was injected intraperitoneally once a day for fourteen days into RA and MS models with different pathogenesis.</p> <p><b>RESULTS:</b> Methotrexate showed strong ameliorative effects in classical RA models such as CIA and PIA as well as in MS and EAE models. Methotrexate acts only prior to and dependent on T-cell activation in T-cell activated diseases. [4]</p>
Cell Research	Methotrexate (MTX) is dissolved in DMSO and stored, and then diluted with appropriate media before use[1]. Each cell line is studied in growth inhibition experiments using 96-well microtiter plates. As antifols are schedule dependent, preliminary experiments are aimed at defining the longest duration of exposure that would allow for continuous logarithmic phase growth of cells without changing of the culture media while maintaining a linear relationship between SRB optical density and cell number. Twenty-four hours after cell plating, the cell lines are exposed to the antifol for 120 h (three

Cell Research	replicates per experiment). To ensure that a complete sigmoidal survival-concentration curve could be observed, the following drug concentrations are studied: Methotrexate (0.002-5 $\mu$ M), AMT (0.0001-1 $\mu$ M), PXD (0.0003-10 $\mu$ M), TLX (0.0002-0.5 $\mu$ M). Experiments are repeated at least twice[1].
---------------	---

### Solubility Information

Solubility	DMSO: 70 mg/mL (154.04 mM), Sonication is recommended. Ethanol: < 1 mg/mL (insoluble or slightly soluble), (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 8.3 mg/mL (18.26 mM), Suspension. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2005 mL	11.0026 mL	22.0051 mL
5 mM	0.4401 mL	2.2005 mL	4.401 mL
10 mM	0.2201 mL	1.1003 mL	2.2005 mL
50 mM	0.044 mL	0.2201 mL	0.4401 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Norris RE, et al. Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias. *Cancer Chemother Pharmacol.* 2010 May;65(6):1125-30.
- Li X, Xi B, Miao Y, et al. Nintedanib ameliorates imiquimod-induced psoriasis in mice by inhibiting NF- $\kappa$ B and VEGFR2 signaling. *International Immunopharmacology.* 2021, 100: 108129.
- AlBasher G, et al. Methotrexate-induced apoptosis in human ovarian adenocarcinoma SKOV-3 cells via ROS-mediated bax/bcl-2-cyt-c release cascading. *Onco Targets Ther.* 2018 Dec 17;12:21-30.
- Zhao Y, Li Y, Zhu R, et al. RPS15 interacted with IGF2BP1 to promote esophageal squamous cell carcinoma development via recognizing m6A modification. *Signal Transduction and Targeted Therapy.* 2023, 8(1): 224.
- Freeman-Narrodd M, et al. Chronic toxicity of methotrexate in mice. *J Natl Cancer Inst.* 1977 Mar;58(3):735-41.
- Kutbi D, Almalki R S. Valsartan Mitigates the Progression of Methotrexate-Induced Acute Kidney Injury in Rats via the Attenuation of Renal Inflammation and Oxidative Stress. *Journal of Inflammation Research.* 2024: 2233-2243.
- Lange F, et al. Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis. *Ann Rheum Dis.* 2005 Apr;64(4):599-605.
- Du J, Zou Q, Shen Y, et al. Monotropin mitigates methotrexate-induced liver injury by activating autophagy and inhibiting ferroptosis. *Journal of Functional Foods.* 2024, 121: 106413.
- Chen K, Gao Y, Xia N, et al. Long-term therapeutic effects of allogeneic mesenchymal stem cell transplantation for intrauterine adhesions. *Stem Cell Research & Therapy.* 2024, 15(1): 1-13.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481